Overview

Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS

Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to proof the efficacy and safety of 20 mg (2 tablets of 10 mg) VAC BNO 1095 film-coated tablets in patients suffering from cyclic mastodynia and PMS (pre menstrual syndrome).
Phase:
Phase 3
Details
Lead Sponsor:
Bionorica SE